190367-56-7

Basic information

• Product Name: Methyl 4-chloro-2-Methyl-5-nitrobenzoate
• Synonyms: Methyl 4-chloro-2-Methyl-5-nitrobenzoate;4-Chloro-2-methyl-5-nitro-benzoic acid methyl ester
• CAS NO: 190367-56-7
• Molecular Formula: C₉H₈ClNO₄
• Molecular Weight: 229.61712
• Mol File: 190367-56-7.mol

Chemical Properties

• Boiling Point: 335.8±37.0 °C(Predicted)
• Appearance: /
• Density: 1.371±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: Methyl 4-chloro-2-Methyl-5-nitrobenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 4-chloro-2-Methyl-5-nitrobenzoate(190367-56-7)
• EPA Substance Registry System: Methyl 4-chloro-2-Methyl-5-nitrobenzoate(190367-56-7)

Safety Data

• Hazardous Substances Data: 190367-56-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Methyl 4-chloro-2-methyl-5-nitrobenzoate is used as an active pharmaceutical ingredient for its antimicrobial and anti-inflammatory properties. It contributes to the development of medications that target a wide range of infections and inflammations, enhancing the therapeutic effects of the final products.
Used in Agrochemical Industry:
In the agrochemical sector, Methyl 4-chloro-2-methyl-5-nitrobenzoate is utilized as a key component in the formulation of pesticides and fungicides. Its antimicrobial properties help protect crops from various diseases and pests, ensuring higher yields and better crop quality.
Safety Precautions:
It is important to handle Methyl 4-chloro-2-methyl-5-nitrobenzoate with care, as it may cause skin and eye irritation. Additionally, it can be harmful if ingested or inhaled. Proper safety measures, such as wearing protective gear and working in well-ventilated areas, should be taken to minimize the risk of exposure.

Upstream product

• 67-56-1 methanol 
• 476660-41-0 4-chloro-2-methyl-5-nitrobenzoic acid 
• 7499-07-2 4-chloro-2-methylbenzoic acid 
• 950915-10-3 4-chloro-2-methyl-3-nitro-benzoic acid 
• 74-11-3 para-chlorobenzoic acid 

Downstream Products

• 863885-79-4 methyl 2-methyl-4-(methylamino)-5-nitrobenzoate 
• 390816-48-5 4-cyclohexylamino-2-methyl-5-nitrobenzoic acid methyl ester 
• 390816-49-6 4-cyclohexylamino-2-methyl-3-nitrobenzoic acid methyl ester 

Relevant articles and documents

Identification of a Benzimidazolecarboxylic Acid Derivative (BAY 1316957) as a Potent and Selective Human Prostaglandin E2 Receptor Subtype 4 (hEP4-R) Antagonist for the Treatment of Endometriosis

The presence and growth of endometrial tissue outside the uterine cavity in endometriosis patients are primarily driven by hormone-dependent and inflammatory processes - the latter being frequently associated with severe, acute, and chronic pelvic pain. T

BENZOIMIDAZOLE DERIVATIVES AS PAD4 INHIBITORS

Compounds of formula (I): wherein X, Y, R1 and R3-R11 are as herein defined, and salts thereof are PAD4 inhibitors and may be useful in the treatment of various disorders, for example rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis, cancer, cystic fibrosis, asthma, cutaneous lupus erythematosis, and psoriasis.

Viral polymerase inhibitors

An isomer, enantiomer, diastereoisomer, or tautomer of a compound, represented by formula I: wherein R1 is selected from: H, haloalkyl, (C1-6)alkyl, (C2-6)alkenyl, (C3-7)cycloalkyl, (C2-6)alkynyl, (C5-7)cycloalkenyl, 6 or 10-membered aryl, Het all optionally substituted; R2 is selected from (C1-6)alkyl, (C3-7)cycloalkyl, (C6-10)bicycloalkyl, 6- or 10-membered aryl, or Het all optionally substituted; B is N or CR5, wherein R5 is H, halogen, haloalkyl, (C1-6)alkyl, (C3-7)cycloalkyl or (C1-6)alkyl-(C3-7)cycloalkyl; X is N or CR5; D is N or CR5; each of Y1 and Y2 is independently O or S; Z is O, N, or NRz wherein Rz is H, (C1-6)alkyl, (C3-7)cycloalkyl or (C1-6)alkyl-(C3-7)cycloalkyl; R3 and R4 are each independently H, (C1-6)alkyl, first (C3-7)cycloalkyl or 6- or 10-membered aryl, Het (C1-6)alkyl-6- or 10-membered aryl, (C1-6)alkyl-Het; or each R3 and R4 are independently covalently bonded together to form second (C3-7)cycloalkyl, or heterocycle, all optionally substituted; or when Z is N, either R3 or R4 are independently covalently bonded thereto to form a nitrogen-containing heterocycle; R7 is H, (C1-6 alkyl), (C3-7)cycloalkyl or (C1-6)alkyl-(C3-7)cycloalkyl; or R7 is covalently bonded to either of R3 or R4 to form a heterocycle; A is (C1-6) alkyl-CONHR8 wherein R8 is-6- or 10-membered aryl, or Het; or A is a 6- or 10-membered aryl, or Het said aryl or Het being optionally substituted; or a salt or a derivative thereof; such compounds being potent inhibitors of HCV NS5B polymerase.

(2-methyl-5-(methylsulfonyl)benzoyl)guanidine Na+/H+ antiporter inhibitors

The inhibition of the Na+/H+ exchanger during cardiac ischemia and reperfusion has been shown to be beneficial for the preservation of the cellular integrity and functional performance. The aim of the present investigation was to come up with potent and selective benzoylguanidines as NHE inhibitors for their use as an adjunctive therapy in the treatment of acute myocardial infarction. During the course of our investigations it became clear that the substitution ortho to the acylguanidine was of crucial importance for the potency of the compounds. 4-Chloro and 4-fluoro-2- methylbenzoic acids 6 and 7 were prepared using the directed ortho metalation technique with the carboxylic acid as the directing group. With the LDA/methyl iodide system the 2-methyl group could be extended to an ethyl group. 4-Alkyl groups were inserted by the palladium-catalyzed cross-coupling reaction into the 4-bromo-2-methylbenzoic acid methyl ester (20). Starting with benzoic acids 6-19, the methylsulfonyl group was introduced by a sequence of standard reactions (sulfochlorination, reduction, and methylation). 4-Aryl derivatives 6875 were synthesized by the palladium- catalyzed Suzuki reaction. A large number of nucleophilic displacement reactions in the 4-position were carried out with S-, O-, and N-nucleophiles as well as with the cyano and trifluoromethyl group. Using the ester method, acid chlorides, or Mukaiyama's procedure, the 5-(methylsulfonyl)benzoic acid derivatives were finally converted to the (5- (methylsulfonyl)benzoyl)guanidines 165-267 with excessive guanidine. In some cases nucleophilic substitutions with pyridinols and piperidine derivatives were carried out at the end of the reaction sequence with the 4-halo-N- (diaminomethylene)-5-(methylsulfonyl)benzamides. Variations in the 4-position were most reasonable, but the volume of the substituents was of crucial importance. Substitution in the 3- and particularly in the 6-position led to considerable worsening of the inhibitory effects of the Na+/H+ exchanger. The 2-methyl compounds, however, showed without exception higher in vitro activities than their respective demethyl counterparts as they are exemplified by the reference compounds 266 and 267, obviously caused by a conformational restriction of the acylguanidine chain. The development compound (2-methyl-5-(methylsulfonyl)-4-pyrrolobenzoyl)guanidine, methanesulfonate (246) is a NHE-1 subtype specific NHE inhibitor, being 27- fold more potent toward the NHE-1 than the NHE-2 isoform, 246 was found to act cardioprotectively not only when given before an experimentally induced ischemia, but also curatively after the onset of symptoms of acute myocardial infarction when given prior to the induction of reperfusion.